MedTrace Logo

Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.

NCT07380022 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-02

No results posted yet for this study

Summary

The primary objective of the present postdoctoral research is to evaluate the acceptability and adherence of two dietary supplements containing microbial phytase, Goodphyte IB Defense and Goodphyte Immunity, in adult individuals with chronic diseases, namely Idiopathic Inflammatory Bowel Diseases (IIBD)-that is, Crohn's disease (CD) or Ulcerative Colitis (UC)-Arterial Hypertension (AH), Anemia (AN), or Multiple Sclerosis (MS).

Secondarily, this study will investigate potential changes in iron and zinc absorption following phytase supplementation in these individuals and, consequently, possible changes in their quality of life.

Conditions

Interventions

DIETARY_SUPPLEMENT

Dietary supplement intervention Goodphyte IB Defense

Participants will receive orally Goodphyte IB Defense at a dose of four capsules per day for a duration of two weeks.

DIETARY_SUPPLEMENT

Dietary supplement intervention Goodphyte Immunity

Participants will receive orally Goodphyte IB Immunity at a dose of four capsules per day for a duration of two weeks.

Sponsors & Collaborators

  • University of Thessaly

    lead OTHER

Principal Investigators

  • ODYSSEAS ANDROUTSOS · School of Physical Education, Sport Science and Dietetics

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-09
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07380022 on ClinicalTrials.gov